Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05810480

PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G

Prospective Multicenter Study: PredIcting SterOid DepeNdEnt LivEr Injury (PIONEER) with Polyreactive Immunoglobulin G

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Hannover Medical School · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The investigators identified polyreactive immunoglobulin G (pIgG) in adults (published in Hepatology: https://doi.org/10.1002/hep.32134) and children (in preparation). Quantification of these pIgG using a "home-made" ELISA facilitates the diagnosis of autoimmune hepatitis (AIH) as compared to non-AIH liver diseases and healthy controls. Positivity for pIgG was independent from ANA/SMA positivity and equally diagnostic for AIH even when conventional autoantibodies (ANA/SMA/SLA/LKM) were negative. Additionally, the frequency of pIgG was lower than conventional autoantibodies (ANA, SMA) in vaccinia/drug associated severe liver injury in a retrospective multicenter study after Covid-19 vaccination (https://doi.org/10.1016/j.jhepr.2022.100605). Aims of the study The study aims to evaluate the diagnostic capacity of pIgG to predict AIH in comparison to other liver diseases prospectively. To avoid diagnostic inaccuracy between AIH with long-term need for an immunosuppression and drug induced liver injury with autoimmune features, which can be indistinguishable from AIH at baseline and which has a very low relapse rate after a short steroid course, a follow-up after six months is obligatory for inclusion. Therefore, the investigators will collect one serum sample from every patient (without immunosuppressive treatment) that presents to the respective hospital for evaluation of liver disease by liver biopsy within one year after initiation of the study and that provided written informed consent. Follow-up for evaluation of steroid dependency at six months after diagnosis is obligatory.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTpolyreactive immunoglobulin GPolyreactive immunoglobulin G will be tested centralized in Hannover as published (Taubert, Engel et al., Hepatology, 2022). The current standard diagnostic autoantibodies (e.g. ANA, anti-SMA, anti-LKM, anti-LC1, anti-SLA/L) will be tested centrally in Hannover according to current guidelines.

Timeline

Start date
2023-06-06
Primary completion
2026-07-01
Completion
2027-01-01
First posted
2023-04-12
Last updated
2024-10-16

Locations

8 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT05810480. Inclusion in this directory is not an endorsement.